Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System

Frontiers in Oncology

Hamed Shoorei¹  Mohammad Mehdi Hassanzadeh Taheri¹  Atefe Abak²  Soudeh Ghafouri-Fard³  Amin Agabalazadeh⁴  Guive Sharifi⁵  Mohammad Taheri⁶ 

[1] Department of Anatomical Sciences, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran;Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran;Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran;Department of Pharmacology, Tabriz University of Medical Sciences, Tabriz, Iran;Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

关键词: long non-coding RNA;    lncRNA;    chemoresistance;    brain tumor;    expression;   

DOI  :  10.3389/fonc.2021.670917

来源: DOAJ

【 摘 要 】

Tumors of the nervous system can be originated from several locations. They mostly have high mortality and morbidity rate. The emergence of resistance to chemotherapeutic agents is a hurdle in the treatment of patients. Long non-coding RNAs (lncRNAs) have been shown to influence the response of glioblastoma/glioma and neuroblastoma to chemotherapeutic agents. MALAT1, NEAT1, and H19 are among lncRNAs that affect the response of glioma/glioblastoma to chemotherapy. As well as that, NORAD, SNHG7, and SNHG16 have been shown to be involved in conferring this phenotype in neuroblastoma. Prior identification of expression amounts of certain lncRNAs would help in the better design of therapeutic regimens. In the current manuscript, we summarize the impact of lncRNAs on chemoresistance in glioma/glioblastoma and neuroblastoma.

【 授权许可】

Unknown